e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cost-effectiveness of budesonide/formoterol added to tiotropium in COPD patients in Canada, Australia and Sweden
N. Mittmann, P. Hernandez, C. Mellström, L. Brannman, T. Welte (Halifax, Canada; Lund, Sweden; , Germany)
Source:
Annual Congress 2010 - Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Session:
Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Session type:
Oral Presentation
Number:
5183
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Mittmann, P. Hernandez, C. Mellström, L. Brannman, T. Welte (Halifax, Canada; Lund, Sweden; , Germany). Cost-effectiveness of budesonide/formoterol added to tiotropium in COPD patients in Canada, Australia and Sweden. Eur Respir J 2010; 36: Suppl. 54, 5183
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Cost-effectiveness of adding budesonide/formoterol to tiotropium in severe COPD patients in four Nordic countries
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/ fluticasone propionate (SFC) is well tolerated in patients with COPD over three years
Source: Eur Respir J 2006; 28: Suppl. 50, 34s
Year: 2006
Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe COPD in France
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Benefit of budesonide/formoterol compared with salmeterol/fluticasone in COPD patients in the morning
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009
Economic evaluation of salmeterol/fluticasone propionate combination vs budesonide/formoterol in Spain
Source: Annual Congress 2003 - Management of asthma in primary care
Year: 2003
Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
The occurrence of pneumonia in COPD patients treated with salmeterol xinafoate 50mcg/fluticasone propionate 250mcg (SFC250) – Interim report of post-marketing surveillance in Japan
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
Economic evaluation of salmeterol/fluticasone combination
versus
budesonide plus formoterol in Spain
Source: Eur Respir J 2001; 18: Suppl. 33, 49s
Year: 2001
Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010
Asthma exacerbations in children receiving montelukast vs. other controllers in Italy
Source: Eur Respir J 2005; 26: Suppl. 49, 618s
Year: 2005
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain
Source: Eur Respir J 2006; 28: Suppl. 50, 683s
Year: 2006
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years
Source: Eur Respir J 2006; 28: Suppl. 50, 34s
Year: 2006
The efficacy of salmeterol xinafoate (SX) in the treatment of COPD during 6-month‘s in conditions of Eastern Siberia (ES)
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept